Cardio Diagnostics Holdings Inc.

Cardio Diagnostics Holdings Inc. is a biotechnology company in the healthcare sector that develops and commercializes epigenetics-based clinical tests for cardiovascular disease prevention, early detection, and management. Its primary offerings include Epi+Gen CHD, a three-year symptomatic coronary heart disease risk assessment blood test targeting events like heart attacks; PrecisionCHD, an integrated epigenetic-genetic blood test for detecting coronary heart disease; and Actionable Clinical Intelligence, a platform delivering epigenetic and genetic insights to clinicians for improved chronic care management. The company also provides CardioInnovate360, a research-use-only solution supporting biopharmaceutical discovery and validation for cardiovascular diseases, and HeartRisk, a SaaS platform offering real-time cardiovascular risk intelligence from aggregated clinical data. Cardio Diagnostics Holdings Inc. serves telemedicine providers, concierge practices, longevity clinics, risk-bearing provider organizations, employer organizations, and correctional facilities, leveraging AI-driven multi-omics technology for personalized molecular insights beyond traditional risk factors. Founded in 2017 and headquartered in Chicago, Illinois, it focuses on making cardiovascular care more accessible and precise.

Sector

Healthcare

Industry

Biotechnology

CEO

Dr. Meeshanthini V. Dogan Ph.D.

Employees

15

Headquarters

Chicago, IL, United States

Website

cdio.ai